NASDAQ:AADI Aadi Bioscience (AADI) Stock Price, News & Analysis $3.06 -0.01 (-0.33%) As of 11/13/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC Filings About Aadi Bioscience Stock (NASDAQ:AADI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aadi Bioscience alerts:Sign Up Key Stats Today's Range$2.91▼$3.1150-Day Range$2.89▼$4.6352-Week Range$1.21▼$3.81Volume212,183 shsAverage Volume261,100 shsMarket Capitalization$75.57 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aadi Bioscience is a biopharmaceutical company focused on developing and commercializing therapies for cancers associated with specific genetic alterations. Its work has centered on precision medicines intended for patients with rare or difficult-to-treat tumors. The company’s lead product is FYARRO, an albumin-bound formulation of sirolimus. In the United States, FYARRO is approved for adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor, a rare cancer also known as malignant PEComa. Aadi’s activities have included research and clinical development as well as U.S. commercialization of FYARRO. The company has focused primarily on the U.S. market; information about broader geographic operations and leadership is not included here.AI Generated. May Contain Errors. Read More Receive AADI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aadi Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AADI Stock News HeadlinesPancreatic Endocrine Tumor Market Set to Witness Significant Growth During the Forecast Period (2025–2034) Owing to the Expected Launch of Therapies | DelveInsightOctober 13, 2025 | finance.yahoo.comWhitehawk Therapeutics May 2025 slides: Pivoting to ADC development with three candidatesMay 15, 2025 | uk.investing.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business. | Porter & Company (Ad)Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsightMay 14, 2025 | finance.yahoo.comMarginal Benefits in High-Risk Ovarian Cancer With Addition of Bevacizumab to ChemoMay 13, 2025 | msn.comFYARRO Sets New Standard in Rare Oncology Market with Strong Growth Prospects | DelveInsightApril 17, 2025 | finance.yahoo.comWhitehawk Therapeutics files to sell 41.67M shares of common stock for holdersApril 2, 2025 | markets.businessinsider.comWhitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken PharmaceuticalsMarch 26, 2025 | finance.yahoo.comSee More Headlines AADI Stock Analysis - Frequently Asked Questions How have AADI shares performed this year? Aadi Bioscience's stock was trading at $2.47 at the beginning of 2026. Since then, AADI stock has increased by 23.9% and is now trading at $3.06. How were Aadi Bioscience's earnings last quarter? Aadi Bioscience, Inc. (NASDAQ:AADI) released its quarterly earnings data on Tuesday, March, 18th. The company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.37. The company earned $7.24 million during the quarter, compared to analyst estimates of $7.45 million. Aadi Bioscience had a negative net margin of 246.06% and a negative trailing twelve-month return on equity of 71.87%. Read the conference call transcript. When did Aadi Bioscience's stock split? Aadi Bioscience shares reverse split before market open on Friday, August 27th 2021.The 1-15 reverse split was announced on Thursday, August 26th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 25th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Aadi Bioscience? Shares of AADI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aadi Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aadi Bioscience investors own include Pfizer (PFE), iBio (IBIO), Ford Motor (F), NIO (NIO), Nokia (NOK), Advanced Micro Devices (AMD) and Bionano Genomics (BNGO). Company Calendar Today11/14/2026Jefferies Global Healthcare Conference11/16/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AADI CIK1422142 Webaadibio.com Phone(424) 473-8055FaxN/AEmployees40Year Founded2011Profitability EPS (Trailing Twelve Months)($2.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$65.76 million Net Margins-246.06% Pretax Margin-246.06% Return on Equity-71.87% Return on Assets-57.28% Debt Debt-to-Equity RatioN/A Current Ratio4.89 Quick Ratio4.54 Sales & Book Value Annual Sales$25.07 million Price / Sales3.01 Cash FlowN/A Price / Cash FlowN/A Book Value$4.29 per share Price / Book0.71Miscellaneous Outstanding Shares24,697,000Free Float15,485,000Market Cap$75.57 million OptionableNo Data Beta0.68 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:AADI) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredSHOCKING! Prediction caught on cameraNewly released footage shows James Altucher pulling a document out of a briefcase on camera. It is a document ...Paradigm Press | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aadi Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aadi Bioscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
